PredictImmune announces new framework agreement with Cambridge Enterprise to allow future expansion of original IP license to expand its commercial product pipeline; extending the benefits of prognostic testing to include systemic lupus erythematosus

The agreement will enable PredictImmune to broaden its product range through the development and commercialisation of a prognostic test for SLE PredictImmune developers of pioneering prognostic tools for guiding treatment options and improving patient outc...